TY  - JOUR
AU  - Denniston, Elizabeth 
AU  - Crewdson, Hannah 
AU  - Rucinsky, Nicole 
AU  - Stegman, Andrew 
AU  - Remenar, Diana 
AU  - Moio, Katherine 
AU  - Clark, Brianne 
AU  - Higginbotham, Alexandra 
AU  - Keffer, Ross 
AU  - Brammer, Sarah 
AU  - Horzempa, Joseph 
PY  - 2016
TI  - The Practical Consideration of Poliovirus as an Oncolytic Virotherapy
JF  - Current Research in Virology
VL  - 5
IS  - 1
DO  - 10.3844/ajvsp.2016.1.7
UR  - https://thescipub.com/abstract/ajvsp.2016.1.7
AB  - The inauguration of novel treatment strategies into the clinical setting faces a number of hurdles. In addition to treatment efficacy and safety, acceptance by doctors and patients is paramount to the success of novel therapies. Although viruses are the cause of numerous infectious diseases, these acellular entities have been harnessed over the years to benefit mankind. Recently, a recombinant Poliovirus-Rhinovirus Chimera (PVSRIPO) has shown promise for the treatment of glioblastoma in clinical trials as well as other cancer types in animal models. In this literature review, we discuss the use of PVSRIPO as an oncolytic virotherapy. In addition to being a potential treatment for glioblastoma, this recombinant virus could possibly be used against other cancers because many tumor cells express the PVSRIPO receptor antigens (CD155) and have a limited ability to control viral replication. Moreover, virus-induced immune responses contribute to the efficacy of PVSRIPO. Given the current trajectory of this experimental therapy, the possibility exists that PVSRIPO will soon be a viable treatment option for various cancer types. While many healthcare providers and cancer patients likely welcome this new viral based treatment, history has taught us that some may be skeptical and avoid its use because of the viral composition of this therapy.